摘要
过去10年,国外肺动脉高压(PH)领域取得了重要进展,尤其是在治疗方面。由传统的吸氧、强心、利尿、钙通道阻滞剂和抗凝等,向针对发病机制本身的靶向治疗突破,使得PH患者的存活率和生存质量明显改观。但我国多数临床医生对PH的诊治意识不高,致使PH患者检出率低,影响了患者的预后。
pulmonary hypertension（PH） abroad made a great progress in the past ten years, especially in the therapeutic areas. The therapy of PH had a breakthrough in the traditional oxygen, enhance myocardial contractile force, diUretic, CalciUm antagonist and anticoagulant, transferring to the targeted therapy. The quality of life and survival of the patients with PH had been improved significantly. The longevity of these patents had been influenced by the poor diagnostic awareness of our country most clinical doctors.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2011年第3期226-228,共3页
Chinese Journal of Practical Internal Medicine
关键词
肺动脉高压
靶向药物
pulmonary arterial hypertension
target drugs
